Acitretin Market – By Product Type (Branded, Generics), Dosage Strength (10 mg, 25 mg, 50 mg), Application (Psoriasis, Ichthyosis, Darier Disease), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), End-use – Global Forecast (2024 – 2032)

Acitretin Market Size

Acitretin Market size was valued at around USD 33.8 million in 2023 and is estimated to grow at 4.6% CAGR from 2024 to 2032. Acitretin is a pharmaceutical agent belonging to the class of retinoids, derivatives of vitamin A. It is primarily used in the treatment of severe psoriasis, a chronic inflammatory skin disorder characterized by thickened, scaly patches of skin. Acitretin is available in oral capsule form and works by modulating the growth and development of skin cells, reducing inflammation, and promoting the shedding of excess skin cells.
 

The increasing prevalence of psoriasis and psoriasis treatment serves as a substantial impetus for market growth. For instance, according to information sourced from the National Library of Medicine in 2021, the prevalence of psoriasis varies, with rates in adults ranging from 0.91% to 8.5%, and in children 2.1%. Globally, an estimated 125 million people, constituting approximately 2–3% of the total population are affected by psoriasis. Thus, this underscores the significant demand for effective treatment options such as acitretin, driving market growth for medications targeting psoriasis management. Furthermore, advancements in treatment, expanding healthcare infrastructure, and growing awareness and diagnosis are the contributing factors stimulating the growth of the market.

Acitretin Market Trends

Advancements in the treatment of psoriasis have transformed the landscape of dermatological care offering patients with this chronic skin condition a wider array of effective therapeutic options. Among these treatments, acitretin has emerged as a cornerstone medication providing notable benefits in managing moderate to severe cases of psoriasis. With a focus on enhancing efficacy, improving safety profiles, and optimizing patient outcomes, advancements in acitretin therapy have reshaped the way healthcare professionals approach psoriasis treatment.
 

• Continued research and clinical trials have provided evidence of the efficacy of acitretin in controlling psoriatic symptoms, particularly in cases of moderate to severe psoriasis. Acitretin has been shown to effectively reduce inflammation, normalize skin cell growth, and alleviate symptoms such as redness, scaling, and thickness of lesions.
   
• Advancements in understanding the genetic and immunological factors contributing to psoriasis have led to the development of personalized treatment approaches. Tailoring acitretin therapy based on individual patient characteristics can optimize treatment outcomes.
   
• Additionally, acitretin is often used in combination with other psoriasis treatments  such as topical corticosteroids, phototherapy, or biologic agents to enhance efficacy and reduce the dosage required, thereby minimizing side effects. Thus, escalating the growth of the market.
   

Acitretin Market Analysis

Based on product type, the market is divided into branded and generics. The branded segment is estimated to account for USD 24.3 million by the end of 2032.
 

• Branded versions of acitretin are often manufactured by reputable pharmaceutical companies with stringent quality control measures in place. This ensures consistency in product formulation, potency, and purity, contributes to more predictable treatment outcomes.
   
• Certain brands may innovate in terms of formulation, offering unique delivery systems or formulations that enhance the drug's bioavailability, reduce side effects, or improve patient convenience. These advancements may result in a more effective and tolerable treatment experience for patients.
   
• Further, branded pharmaceutical companies often invest in ongoing research and development efforts to improve existing medications and develop new treatment options. This commitment to innovation may lead to the discovery of novel therapeutic approaches, further advancing the field of dermatology drugs, which is estimated to reach USD 73.5 billion by 2032, and benefiting patients with psoriasis.
   

Based on dosage strength, the acitretin market is bifurcated into 10 mg, 25 mg, and 50 mg. The 25mg segment accounted for USD 16 million in 2023.
 

• Acitretin is often prescribed at different dosages based on the severity of the condition and individual patient response. The 25mg dosage allows for more precise dosing adjustments particularly in cases where lower doses are required to achieve therapeutic efficacy while minimizing side effects.
   
• Lower dosages of acitretin such as 25mg may result in a reduced incidence and severity of side effects compared to higher doses. This can lead to improved tolerability and adherence to treatment, as patients are less likely to experience adverse reactions that may affect their quality of life.
   
• Further, the availability of a 25mg dosage option for acitretin offers healthcare providers enhanced flexibility in tailoring treatment plans to meet the unique needs and preferences of individual patients.
   

Based on application, the acitretin market is divided into psoriasis, ichthyosis, Darier disease, pityriasis rubra pilaris, solid organ transplants, Grover’s disease, lichen planus, and lupus erythematosus. The psoriasis segment is estimated to account for USD 21.4 million by 2032.
 

• Acitretin has been demonstrated to be effective in the treatment of moderate to severe psoriasis, including plaque psoriasis, guttate psoriasis, and pustular psoriasis. It helps to reduce the severity of symptoms such as inflammation, scaling, and erythema, improving the overall appearance of the skin and enhancing quality of life for patients.
   
• It is administered orally, offers convenience for patients compared to topical treatments that require frequent application. This route of administration allows for systemic distribution of the medication, targeting psoriatic lesions throughout the body.
   
• Further, acitretin can be used for long-term maintenance therapy in patients with chronic psoriasis, helping to control disease flares and prevent recurrence of symptoms. It offers a viable treatment option for patients who require ongoing management of their psoriasis symptoms. Thus, propelling the growth of the market.
   

Based on distribution channel, the acitretin market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is estimated to account for USD 21.7 million by 2032.

• Hospital pharmacies have access to a wide range of medications including branded and generic formulations of acitretin. This allows healthcare providers to select the most suitable option based on patient needs, preferences, and formulary restrictions.
   
• Hospital pharmacists are highly trained professionals with expertise in medication management and therapeutic optimization. They can provide specialized knowledge and guidance on the appropriate use of acitretin including dosing regimens, drug interactions, and monitoring parameters.
   
• Further, hospital pharmacies may offer specialized services such as compounding, medication reconciliation, and medication therapy management (MTM) programs, to support patients receiving acitretin therapy. These services enhance medication adherence, safety, and patient outcomes.
   

U.S. acitretin market is anticipated to grow at CAGR of 4.4% during the analysis timeframe.
 

• The U.S. has a highly developed pharmaceutical industry with advanced manufacturing capabilities. This allows for the production of high-quality acitretin products meeting stringent regulatory standards.
   

• It has a significant prevalence of psoriasis. For instance, according to the National Institutes of Health (NIH) in 2021, approximately 3% of adults in the U.S., representing over 7.5 million individuals affected by the psoriasis.
   

The acitretin market in Germany is expected to experience significant and promising growth from 2024 to 2032.
 

• Germany boasts a sophisticated healthcare system renowned for its quality and accessibility. This system ensures that medications such as acitretin are readily available to individuals with psoriasis.
   
• The country is at the forefront of technological innovation in healthcare. This innovation may lead to the development of advanced formulations and delivery methods for acitretin, enhancing its efficacy and ease of use.
   

UK is anticipated to witness robust growth in the global acitretin market.
 

• The UK Medicines and Healthcare products Regulatory Agency (MHRA) oversees the regulation of pharmaceutical products. This ensures that acitretin products marketed in the UK meet high standards of safety, quality, and efficacy.
   
• The country is home to leading research institutions and pharmaceutical companies that conduct clinical trials and studies to advance the understanding and treatment of psoriasis. Ongoing research efforts contribute to the development of Acitretin formulations, dosing regimens, and combination therapies, further improving its efficacy and safety profile.
   

South Korea acitretin market is expected to grow significantly over the years.
 

• South Korea boasts a modern healthcare system with advanced medical facilities and technologies. This infrastructure supports the effective production, distribution, and utilization of medications such as acitretin.
• Additionally, the country is known for its strong focus on research and innovation in healthcare. This commitment to scientific advancement can lead to the development of new formulations and delivery methods for acitretin, enhancing its effectiveness and usability.
   

UAE is anticipated to undergo substantial growth in the coming years.
 

• The UAE has invested heavily in developing state-of-the-art healthcare facilities and services, ensuring high-quality care for its residents. This infrastructure supports the production, distribution, and utilization of medications.
   
• Healthcare providers in the UAE follow clinical guidelines and best practices for the management of psoriasis, include the use of acitretin in certain cases. These guidelines help ensure standardized and evidence-based care for patients, optimizing treatment outcomes.
   

Acitretin Market Share

The acitretin industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products and services based on different technologies is among a key market strategy. Some of the leading industry players have a notable presence in the market.
 

Acitretin Market Companies

Some of the eminent market participants operating in the acitretin industry include:

• Amneal Pharmaceuticals, Inc.                                     
• Biophore.                                   
• Chongqing Huapont Pharmaceutical Co., Ltd.                
• Globe International Limited                              
• GSK Plc                                      
• Merck KGaA                                
• Prasco Laboratories                               
• SGPharma Pvt Ltd                                 
• Sionc Pharmaceuticals Pvt. Ltd.               
• Sun Pharma Industries Limited     
   

Acitretin Industry News:

• In April 2021, Amneal Pharmaceuticals, Inc. completed the acquisition of Kashiv Specialty Pharmaceuticals, LLC. This strategic decision broadened Amneal's portfolio, incorporating a more extensive array of branded products and complex generics, while strengthening its position in the medication market and opening avenues for innovation and growth within the industry.
   

The acitretin market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Branded
• Generics

Market, By Dosage Strength

• 10 mg
• 25 mg
• 50 mg

Market, By Application

• Psoriasis                 
• Ichthyosis              
• Darier disease                   
• Pityriasis rubra pilaris
• Solid organ transplants
• Grover’s disease
• Lichen planus
• Lupus erythematosus                  

Market, By Distribution Channel

• Hospital pharmacies          
• Online pharmacies            
• Retail pharmacies                       

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa